Autoimmune play Syntimmune raises $50M

Autoimmune disease company Syntimmune Inc. (New York, N.Y.) raised $50 million in a series B round. Existing investor Apple Tree Partners invested $48 million to lead the round. Also participating were existing investors Partners Innovation Fund, FMB Research and AFB Fund.

Syntimmune is developing therapies that target the Fc fragment of IgG receptor transporter alpha (FCRN; FCGRT) to selectively tamp down immune pathways activated by IgG antibodies. The company is focusing on diseases associated with high levels of IgG (see BioCentury, Jan. 6)...